BioSpace News Archive

Amphastar Pharmaceuticals, Inc., announces that the U.S. Food and Drug Administration has granted approval of its Abbreviated New Drug Application for Epinephrine Injection, USP 30mg/30mL Multiple Dose Vial.

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological therapeutic products, cordially invites investors, the media, and the public to join a signing ceremony and analyst & investor call on Thursday, April 30, 2020.

Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint)

CARsgen Therapeutics Co., Ltd. announced the European Medicines Agency Committee for Orphan Medicinal Products adopted a positive opinion on CARsgen’s application for orphan designation of its investigational CT053 CAR T-cell therapy, fully human anti-BCMA autologous chimeric antigen receptor T cells for the treatment of multiple myeloma.

JCR Pharmaceuticals Co., Ltd. announced that it has completed the previously announced acquisition of ArmaGen, Inc., a privately held US biopharmaceutical company headquartered in San Diego, California.

COM701 was well-tolerated with no dose-limiting toxicities observed as a monotherapy and in combination with Opdivo® (nivolumab)

TriLink BioTechnologies®, a Maravai LifeSciences company and a leader in the production of nucleic acids for research, diagnostics and therapeutics applications, and Imperial College London, a public research university located in the United Kingdom, announced that they have entered into a partnership in which TriLink will manufacture self-amplifying RNA for COVID-19 vaccine development.

Test Site Finder Now Integrated into Google Search and Adopted by State Governments, Fortune 500 Companies, and Health Plans for Official COVID-19 Response

Avellino announced that it has partnered with the OC Health Care Agency to launch the OC COVID-19 Testing Network.

$50 Million Series A Financing Led by GV and ARCH Venture Partners with Participation from Partners Innovation Fund